文章：

实体瘤CAR-T治疗的障碍与解决方案

Barriers and solutions for CAR-T therapy in solid tumors 

原文发布日期：2025-06-27 

英文摘要：

Chimeric antigen receptor (CAR)-T cell therapy has emerged as a transformative approach for cancer treatment, particularly in hematologic malignancies. However, barriers in the development of effective CAR-T therapies for solid tumors, including antigenic escape, tumor immunosuppressive microenvironments, severe toxicities, and limitations in preclinical models, hinder its scalability and broader clinical implementation. To overcome these barriers, strategies have been developed in recent years, such as optimizing CAR designs, enhancing CAR-T cell infiltration, neutralizing immunosuppressive cells, remodeling metabolism of CAR-T cells, eliminating antigen escape, mitigating toxicities, advancing preclinical models, and in situ programming CAR-T cells. Here, we discuss current barriers and potential strategies for CAR-T cell therapy in solid tumors. Ultimately, we present perspectives on these advanced strategies for broader clinical adoption of CAR-T cell therapy. 

摘要翻译：

嵌合抗原受体（CAR）-T细胞疗法已成为癌症治疗的一种变革性方法，尤其在血液系统恶性肿瘤中表现突出。然而，针对实体瘤开发有效CAR-T疗法仍存在诸多障碍，包括抗原逃逸、肿瘤免疫抑制微环境、严重毒性反应以及临床前模型的局限性，这些因素阻碍了该疗法的规模化应用和更广泛的临床推广。为突破这些障碍，近年来发展了多种策略，例如优化CAR设计、增强CAR-T细胞浸润、中和免疫抑制细胞、重塑CAR-T细胞代谢、消除抗原逃逸、减轻毒性反应、改进临床前模型以及原位编程CAR-T细胞。本文探讨了当前CAR-T细胞疗法在实体瘤治疗中面临的障碍及潜在策略，并对这些先进技术推动CAR-T疗法更广泛临床应用的前景进行了展望。

原文链接：

Barriers and solutions for CAR-T therapy in solid tumors